Merck drug triggers response in 24 pct of lung cancer patients – Reuters

by lowes1 on October 1, 2013

Merck drug triggers response in 24 pct of lung cancer patients
Reuters
Oct 1 (Reuters) – Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment. Data from the trial is slated for presentation
New Market Research Report: Xalkori (Non-Small Cell Lung Cancer) – Forecast SBWire (press release)
Merck's Immune System-Based Cancer Drug Works in 1 in 4Bloomberg
Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data MarketWatch
4-traders (press release) -DailyFinance
all 10 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: